Argenx Acquires Forte Biosciences for $2.2 Billion to Expand Autoimmune Drug Portfolio
Argenx NV ADR (NASDAQ:ARGX) has agreed to acquire Forte Biosciences Inc (NASDAQ:FBRX) in a cash deal valued at approximately $2.2 billion, or $77 per share for Forte stockholders—a 40% premium over the closing price on Friday. The acquisition aims to bolster Argenx's autoimmune disease pipeline by adding clinical-stage therapies currently being developed for vitiligo and celiac disease with potential applications in other conditions. The move follows strong performance from Argenx’s flagship drug, Vyvgart, which has driven growth across multiple autoimmune indications. However, the acquisition reflects a strategic effort to diversify revenue sources beyond its core product after ending a late-stage trial for an eye disease treatment last year. Both companies expect the transaction to close in Q3 2026.